Aim: To study the results of intravitreal triamcinolone acetonide (TA) for exudative age-related macular degeneration (AMD) among Japanese patients. Methods: 13 eyes of 12 Japanese patients (9 males and 3 females) with subfoveal choroidal neovascularization (CNV) of exudative AMD received intravitreal TA (8 mg). Visual acuity, size of CNV and serous retinal detachment, and complications related to treatment were evaluated for 6 months or longer. Results: Postoperative maximum visual acuity significantly improved (p < 0.05). Postoperative eyes had a greater probability of a reduced size of CNV and/or retinal detachment compared to preoperative eyes. Seven eyes showed increased intraocular pressure (21 mm Hg or over), which was controlled well by medication. Cataract development and advancement were observed in 90% of phakic eyes. No other serious complications were found. Conclusions: Intravitreal TA might be an effective treatment for subfoveal CNV of exudative AMD among Japanese as well as Caucasian patients for a comparatively short period.

Keywords:
Triamcinolone acetonide, Age-related macular degeneration, Choroidal neovascularization, Intraocular pressure, Endophthalmitis
1.
Klein R, Klein BE, Linton KL: Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933–943.
2.
Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205–210.
3.
Frank RN, Puklin JE, Stock C, Canter LA: Race, iris color, and age-related macular degeneration. Trans Am Ophthalmol Soc 2000;98:109–115.
4.
Katz J, Bressler NM, Rahmani B, Tielsch J: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106:1049–1055.
5.
Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T, Nose Y: Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol 2003;87:469–472.
6.
Pauleikhoff D, Koch JM: Prevalence of age-related macular degeneration. Curr Opin Ophthalmol 1995;6:51–56.
7.
The Japanese Age-Related Macular Degeneration Trial (JAT) study group: Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1049–1061.
8.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Arch Ophthalmol 1999;117:1329–1345.
9.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP report 2. Arch Ophthalmol 2001;119:198–207.
10.
Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244–250.
11.
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor ABL: Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol 2004;122:336–340.
12.
Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor ABL, Chua W, Mitchell P, Billson F: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch Ophthalmol 2003;121:667–673.
13.
Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R: Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462–468.
14.
Ranson NT, Danis RP, Ciulla TA, Pratt L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527–529.
15.
Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:24–27.
16.
Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791–796.
17.
Roth DB, Cheieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA: Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279–1282.
18.
Jonas JB, Kreissig I, Degenring RF: Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663–1664.
19.
Parke DW: Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136:918–919.
20.
Sakamoto T, Enaida H, Kubota T, Nakahara M, Yamakiri K, Yamashita T, Yokoyama M, Hata Y, Murata T, Miyata K, Uemura A, Kimura W, Ishibashi T: Incidence of acute endophthalmitis after triamcinolone-assisted pars plana vitrectomy. Am J Ophthalmol 2004;138:137–138.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.